2014
|
|

Abstract: The objectives of this study were to evaluate the relative binding and potencies of three inhibitors of vascular endothelial growth factor A (VEGF), used to treat neovascular age-related macular degeneration, and assess their relevance in the context of clinical outcome. Ranibizumab is a 48 kDa antigen binding fragment, which lacks a fragment crystallizable (Fc) region and is rapidly cleared from systemic circulation. Aflibercept, a 110 kDa fusion protein, and bevacizumab, a 150 kDa monoclonal antibody, each c… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
56
2
1

Publication Types

Select...

Relationship

0
0

Authors

Journals